Document:

Exhibit 10

Exhibit 10.3

[Certance Letterhead]

TRANSACTION BONUS AND SEVERANCE PROTECTION LETTER

January 4, 2005

Mr. Howard Matthews:

Dear Howard,

     Certance LLC, a Delaware limited liability company (the “Company”), considers it essential to foster the continuous employment of the key management personnel of the Company.  In this connection, the Board of
Directors of the Company (the “Board”) recognizes that, in view of the Company’s current desire to merge with another corporation, the possibility of a change of control of the Company exists and that possibility, and the uncertainty and questions
that it may raise, could result in your departure or distraction to the detriment of the Company.  Accordingly, on behalf of the Board, I am pleased to inform you that you have been selected by the Board as a key employee eligible to receive the Transaction
Bonus and certain severance protections described below.

     If you are actively employed by the Company as of the consummation of the “Contemplated Merger” (as defined below) (i) you will be entitled to receive a Transaction Bonus in the amount of $408,398.10 (a
“Transaction Bonus”), subject to your satisfaction of the terms and conditions set forth below, (ii) if at any time within the eighteen month period commencing immediately after the consummation of such Contemplated Merger (the “Severance
Protection Period”) your employment is terminated by the Company (or its successor) without “Cause” or by you for “Good Reason” (each as defined under below) subject to your satisfaction of the terms and conditions set forth below, you
will be entitled to receive a cash payment equal to $900,000 (200% of your aggregate annual base salary and annual bonus for the preceding calendar year) (the “Severance Payments”); provided, however, that, unless otherwise provided by action of
the Board, the Transaction Bonus and the Severance Payments will be payable to you only in the event the Contemplated Merger is consummated prior to July 1, 2005.  Notwithstanding anything to the contrary in this agreement, you acknowledge that if you receive an
offer of employment from Quantum and accept the offer, then you waive any right to claim that the employment arrangement as accepted constitutes Good Reason.

     You will not be entitled to any Severance Payments in the event of (i) your termination of employment for any reason prior to or after the Severance Protection Period or (ii) your termination of employment during the
Severance Protection Period due to any reason other than those described above, including your voluntary resignation of employment without Good Reason, termination of employment by the Company for Cause or your death “Disability” (as defined below) or
retirement.

     Any Transaction Bonus that becomes payable to you hereunder will be paid to you in a lump sum cash payment 120 days following the consummation of the Proposed Merger.  Any Severance Payment that becomes payable to you hereunder
will be paid to you in twelve (12) equal monthly installments (on the first day of each month) commencing with the first day of the month immediately succeeding the month in which your termination of employment occurs.

     In consideration for your opportunity to receive the Severance Payments hereunder, you hereby agree to execute an effective release of claims in a form acceptable to the Company.  Your entitlement to any Severance Payment
hereunder is expressly conditioned upon your execution of an effective release of claims in a form acceptable to the Company.

    For purposes of this letter agreement:

    “Cause” means (i) your substantial failure to satisfactorily perform your reasonably assigned duties to the Company or any of its affiliates (including, without limitation, your failure to use your best efforts to
assist in the structuring or consummation of any strategic alternative for the Company that the Board determines to pursue), which failure is not cured within ten days after your receipt of written notice from the Company describing such failure, (ii) dishonesty
in the performance of your duties to the Company or any of its affiliates (iii) an act or acts on your part constituting a felony under the laws of the United States or any state thereof or crime involving moral turpitude, (iv) your material breach of any
written policies or practices of the Company or any of its affiliates, or (v) any other act or omission by you which is materially injurious to the financial condition or business reputation of the Company or any of its affiliates.  As used in this
definition, the term “Company” shall mean the Company or its successor, as the case may be.

    “Disability” means “long term disability” as such term (or similar term) is defined in the Company’s long-term disability policy as in effect from time to time, or if there should be no such policy or
such term is not defined therein, your inability, due to physical or mental incapacity, to substantially perform your duties to the Company for a period of six (6) consecutive months or for an aggregate of nine (9) months in any twenty-four consecutive month
period.  Any questions as to the existence of the Disability as to which the Company and you cannot agree will be determined by the Company in its sole discretion.

    “Good Reason” means (i) any substantial diminution in your duties or a reduction in your annual base salary or target bonus percentage as in effect at the time of the Contemplated Merger, which diminution or reduction is
not remedied within ten (10) days following written notice from you to the Company describing such diminution or reduction, or (ii) a relocation of your principal workplace more than fifty (50) miles from your principal workplace as of the date hereof made without
your written consent.

    “Contemplated Merger” means the consummation of the merger of Quartz Merger Sub, Inc., a Delaware corporation, with and into the Company, as detailed in that certain Agreement and Plan of Merger (the “Merger
Agreement”) dated October 20, 2004.

     Your entitlement to the payment of the Transaction Bonus and/or Severance Payments hereunder will not be subject to mitigation.  Consequently, you will not be obligated to seek alternative employment in the event of your termination
of employment with the Company or its affiliates (including any successor) and the amount of compensation paid or payable to you hereunder will not be reduced by any compensation paid or payable to you by any future employer.

     Notwithstanding any other provision of this letter agreement, however, the amount of any Severance Payments otherwise payable hereunder are in lieu of any benefit provided under any other severance plan, program, policy or arrangement of
the Company or any of its affiliates (including any successor to the Company or any of its affiliates) in effect at the time of your termination of employment.

     This letter agreement constitutes the entire agreement between you and the Company and it is the complete, final, and exclusive embodiment of our agreement with regard to this subject matter.  It is entered into without reliance on
any promise or representation other than those expressly contained herein.  This letter agreement shall be governed by the laws of the State of California, without reference to the principles of conflict of laws and may be executed in counterparts, each of which
shall constitute an original, but all of which taken together shall constitute one and the same agreement.

     Your rights to the payment of any Transaction Bonus or Severance Payments hereunder may not be assigned, transferred, pledged or otherwise alienated, other than by will or the laws of descent and distribution.

     Unless otherwise determined by the Board, any payments made hereunder shall not be taken into account in computing your salary or compensation for the purposes of determining any benefits or compensation under (i) any pension,
retirement, life insurance or other benefit plan of the Company or any of its affiliates (including any successor to the Company or any of its affiliates) or (ii) any agreement between the Company or any of its affiliates (including any successor to the Company
or any of its affiliates) and you.

     The Company may withhold from the Transaction Bonus and the Severance Payments such Federal, state or local taxes as shall be required to be withheld pursuant to any applicable law or regulation.

     The terms of the Transaction Bonus may not be amended or modified other than by a written instrument executed by parties hereto or their successors and legal representatives.

     Kindly sign this letter agreement in the space indicated below at which time this letter agreement shall become a binding agreement between you and the Company enforceable in accordance with its terms.

Sincerely,

	

                                                                            

	
/s/ Michael D. Cox

		
Michael D. Cox

		
Corporate Controller

Accepted and Agreed to:

	
By:    

	
/s/ Howard Matthews

		
Howard MatthewsAMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

        This
Amended and Restated Stockholders Agreement (this “Agreement”) is
made and entered into as of July 30, 2004 by and among MSO Medical, Inc., a Delaware
corporation (the “Company”), the persons and entities listed on
Exhibit A attached hereto (the “Investors”) and the
persons and entitles listed on Exhibit B attached hereto (the “Common
Holders”). 

        A.    The
Company and certain of the Investors have previously entered into that           certain
Series A Convertible Preferred Stock Purchase Agreement dated March 28,           2004
(the “Prior Series A Agreement”) pursuant to
          which such Investors (the “Prior Series A           Holders”)
purchased shares of the Company’s Series A           Convertible Preferred Stock
(the “Series A Stock”).  

        B.    The
Company and the Prior Series A Holders have also previously entered into           that
certain Stockholders Agreement dated March 28, 2004 (the “Prior
          Agreement”);  

        C.    Each
Common Holder is the beneficial owner of the number of shares of Common           Stock
of the Company (the “Common Stock”) set forth next           to
his, her or its name on Exhibit B hereto.  

        D.    Certain
of the Investors are purchasing additional shares of the Company’s           Series
A Stock pursuant to that certain Series A Convertible Preferred Stock
          Subscription Agreement dated as of even date herewith (the “Purchase
          Agreement”);  

        E.    The
Prior Series A Holders now desire to amend and restate the Prior Agreement           and
accept the rights and covenants hereof in lieu of their rights and covenants
          under the Prior Agreement and to add the new Investors as parties hereto.  

        NOW,
THEREFORE, in consideration of the foregoing recitals and the mutual
promises hereinafter set forth, the parties hereto agree to amend and restate the Prior
Agreement as follows:

        1.   GENERAL. 

		    1.1.           Definitions. As
used in this Agreement the following terms shall           have the following respective
meanings:  

		    (a)           Equity
Securities. The term “Equity           Securities” shall
mean any securities having voting rights           in the election of the Board of
Directors of the Company, or any securities           evidencing an ownership interest in
the Company, or any securities convertible           into, or exchangeable or exercisable
for, any shares of the foregoing, or any           agreement or commitment to issue any
of the foregoing.  

		    (b)           New
Securities. The term “New Securities” shall           mean
any Equity Securities of the Company, whether now authorized or not and
          securities of any type whatsoever that are, or may become, convertible or
          exchangeable into such Equity Securities; provided, however, that the term “New
Securities” does not include:  

		    (1)                     shares
of Common Stock issued or issuable upon conversion of the outstanding           shares of
the Series A Stock;  

		    (2)                     shares
of Common Stock issued or issuable pursuant to stock dividends, stock           splits,
distributions or similar transactions on the Series A Stock and the           Common
Stock;  

		    (3)                     up
to 750,000 shares of Common Stock (or options, warrants or rights therefor)
          (such number of shares to be calculated net of any repurchases and
cancellations           of such shares by the Company and net of any such expired or
terminated options,           or rights and to be proportionally adjusted to reflect any
stock splits, stock           dividends, recapitalizations or the like) granted, issued
or issuable to           employees, officers, directors, contractors, consultants or
advisers to the           Company pursuant to the Company’s 2004 Equity Incentive
Plan;  

		    (4)                     shares
of the Company’s Common Stock, or options, warrants or rights to           purchase
Common Stock, issued or issuable to financial institutions or lessors           in
connection with equipment lease financing arrangements, real estate leases,
          credit arrangements, debt financings or other similar commercial transactions
          approved by the Board of Directors;  

		    (5)                     shares
of Common Stock, or options, warrants or rights to purchase Common Stock,
          issued for consideration other than cash pursuant to a merger, consolidation,
          acquisition or similar business combination approved by the Board of Directors;  

		    (6)                     shares
of Series A Stock issued under the Purchase Agreement, as such           agreement
may be amended;  

		    (7)                     shares
of Common Stock issuable upon exercise of any options, warrants,           convertible
securities or rights to purchase any securities of the Company           outstanding as
of the date of this Agreement and any securities issuable upon           the conversion
thereof; and  

		    (8)                     shares
of the Company’s Common Stock issued or issuable by the Company to           the
public pursuant to a registration statement filed under the Securities Act.  

		    (c)           Qualified
Public Offering. The term “Qualified Public           Offering” means
an underwritten sale of Common Stock of the           Company to the public pursuant to a
registration statement filed with, and           declared effective by, the SEC under the
Securities Act, covering the offer and           sale of Common Stock to the public at an
aggregate gross public offering price           (calculated before deduction of
underwriters’ discounts and commissions) of           at least Fifteen Million
Dollars ($15,000,000).  

		    (d)           Sale.
The term “Sale” shall mean (i) the           acquisition
of the Company by another entity by means of any transaction or           series of
related transactions (including, without limitation, any           reorganization, merger
or consolidation but excluding any merger effected           exclusively for the purposes
of changing the domicile of the Company); or (ii) a           sale, license, assignment
or other disposition of all or substantially all of           the assets of the Company;
unless, in the case of (i) or (ii) the Company’s           stockholders of record as
constituted immediately prior to such acquisition or           sale will, immediately
after such acquisition or sale (by virtue or securities           issued as consideration
for the Company’s acquisition or sale or otherwise           ) hold at least 50% of
the voting power of the surviving or acquiring entity.  

2 

		    (e)           SEC.
The term “SEC” or “Commission” means the
U.S. Securities and Exchange           Commission.  

		    (f)           Securities
Act. The term “Securities Act”          means the
Securities Act of 1933, as amended.  

		    2.           RESTRICTIONS
ON TRANSFER; CONVERSION PRICE ADJUSTMENT. 

		    2.1.                     Except
as otherwise provided in this Agreement, the Common Holders will not           sell,
assign, transfer, pledge, hypothecate, or otherwise encumber or dispose of           in
any way, all or any part of or any interest in the Equity Securities now or
          hereafter owned or held by the Common Holders. Any sale, assignment, transfer,
          pledge, hypothecation or other encumbrance or disposition of Equity Securities
          not made in conformance with this Agreement shall be null and void, shall not
be           recorded on the books of the Company and shall not be recognized by the
Company.  

		    2.2.                     In
addition to the restrictions on transfer set forth elsewhere in this           Agreement,
each Common Holder shall, subject to Section 3.4, retain no less than           ninety
percent (90%) of their Equity Securities held on the date of this           Agreement
until the Investors shall have received one hundred twenty-five           percent (125%)
of their investment in the Series A Stock. The provisions of this           Section 2.2
shall immediately terminate upon the first to occur of (a) the           closing of a
Qualified Public Offering, or (b) the conversion of a majority of           the Series A
Stock into Common Stock.  

		    3.           RIGHT
OF FIRST REFUSAL AND CO-SALE. 

		    3.1.           Right
of First Refusal. 

		    (a)           Transfer
Notice. If at any time any Common Holder proposes to transfer           Equity
Securities to one or more third parties pursuant to an understanding with           such
third parties (a “Transfer”), then the           Common
Holder shall give the Company and each Investor written notice of the           Common
Holder’s intention to make the Transfer (the “Transfer           Notice”),
which Transfer Notice shall include (i) a           description of the Equity Securities
to be transferred (“Offered           Shares”), (ii) the
identity of the prospective           transferee(s), (iii) the date and time of the
closing of the Transfer, and (iv)           the consideration and the other material
terms and conditions upon which the           proposed Transfer is to be made. The
Transfer Notice shall certify that the           Common Holder has received a firm offer
from the prospective transferee(s) and           in good faith believes a binding
agreement for the Transfer is obtainable on the           terms set forth in the Transfer
Notice. The Transfer Notice shall also include a           copy of any written proposal,
term sheet or letter of intent or other agreement           relating to the proposed
Transfer.  

3 

		    (b)           Company’s
Option. The Company shall have an option for a period of           ten (10) days from
receipt of the Transfer Notice to elect to purchase the           Offered Shares at the
same price and subject to the same material terms and           conditions as described
in the Transfer Notice. The Company may exercise such           purchase option, and
thereby, purchase all (or a portion of) the Offered Shares           by notifying the
Common Holder in writing before expiration of such ten (10) day           period as to
the number of such shares which it wishes to purchase. If the           Company gives the
Common Holder notice that it desires to purchase such shares,           then payment for
the Offered Shares shall be by check or wire transfer, against           delivery of the
Offered Shares to be purchased at a place agreed upon between           the parties and
at the time of the scheduled closing therefor, which shall be no           later than
forty-five (45) days after the Company’s receipt of the Transfer           Notice,
unless the Transfer Notice contemplated a later closing with the           prospective
third party transferee(s) or unless the value of the purchase price           has not yet
been established pursuant to Section 3.1(e). If the Company fails to           purchase
all of the Offered Shares by exercising the option granted in this           Section
3.1(b) within the period provided, the Offered Shares shall be subject           to the
options granted to the Investors pursuant to this Agreement.  

		    (c)           Additional
Transfer Notice. Subject to the Company’s right set forth           in Section
3.1(b), if at any time the Common Holder proposes a Transfer, then,           after the
Company has declined to purchase all, or a portion, of the Offered           Shares, the
Common Holder shall give each Investor an “Additional           Transfer Notice” which
shall include all of the information           and certifications required in a Transfer
Notice and shall additionally identify           the Offered Shares which the Company has
declined to purchase (the “Remaining Shares”) and briefly
describe the           Investors’ rights of first refusal and co-sale rights with
respect to the           proposed Transfer.  

		    (d)           Investors’ Option.
The Investors shall have an option for a period           of twenty (20) days from the
Investors’ receipt of the Additional Transfer           Notice from the Common
Holder set forth in Section 3.1(c) to elect to purchase           their respective pro
rata share of the Remaining Shares at the same price and           subject to the same
material terms and conditions as described in the Additional           Transfer Notice.
Each Investor may exercise such purchase option and, thereby,           purchase all or
any portion of his, her or its pro rata share (with any           reallotments as
provided below) of the Remaining Shares, by notifying the Common           Holder and the
Company in writing, before expiration of the twenty (20) day           period as to the
number of such shares which he, she or it wishes to purchase           (including any
reallotment). Each Investor’s pro rata share of the           Remaining Shares shall
be a fraction of the Remaining Shares, of which the           number of Equity Securities
owned by such Investor on the date of the Transfer           Notice shall be the
numerator and the total number of Equity Securities held by           the Common Holder
and all Investors on the date of the Transfer Notice shall be           the denominator.
Each Investor shall have a right of reallotment such that, if           any other
Investor fails to exercise the right to purchase its full pro rata           share of the
Remaining Shares, the other participating Investors may exercise an           additional
right to purchase, on a pro rata basis, the Remaining Shares not           previously
purchased. Each Investor shall be entitled to apportion Remaining           Shares to be
purchased among its partners and affiliates, provided that such           Investor
notifies the Common Holder of such allocation. If an Investor gives the           Common
Holder notice that it desires to purchase its pro rata share of the           Remaining
Shares and, as the case may be, its reallotment, then payment for the           Remaining
Shares shall be by check or wire transfer, against delivery of the           Remaining
Shares to be purchased at a place agreed upon between the parties and           at the
time of the scheduled closing therefor, which shall be no later than           forty-five
(45) days after the Company’s receipt of the Transfer Notice,           unless the
Transfer Notice contemplated a later closing with the prospective           third party
transferee(s) or unless the value of the purchase price has not yet           been
established pursuant to Section 3.1(e).  

4 

		    (e)           Valuation
of Property. Should the purchase price specified in the           Transfer Notice or
Additional Transfer Notice be payable in property other than           cash or evidences
of indebtedness, the Company (or the Investors) shall have the           right to pay the
purchase price in the form of cash equal in amount to the value           of such
property. If the Common Holder and the Company (or the Investors) cannot           agree
on such cash value within ten (10) days after the Company’s receipt           of the
Transfer Notice (or the Investors’ receipt of the Additional           Transfer
Notice), the valuation shall be made by an appraiser of recognized           standing
selected by the Common Holder and the Company (or the Investors) or, if           they
cannot agree on an appraiser within twenty (20) days after the           Company’s
receipt of the Transfer Notice (or the Investors’ receipt of           the
Additional Transfer Notice), each shall select an appraiser of recognized
          standing and the two appraisers shall designate a third appraiser of recognized
          standing, whose appraisal shall be determinative of such value. The cost of
such           appraisal shall be shared equally by the Common Holder and the Company (or
the           Investors pro rata based on the number of shares each Investor was
interested in           purchasing pursuant to this Section 3). If the time for the
closing of the           Company’s purchase (or the Investors’ purchase) has
expired but for           the determination of the value of the purchase price offered by
the prospective           transferee(s), then such closing shall held on or prior to the
fifth business           day after such valuation shall have been made pursuant to this
subsection.  

		    3.2.           Right
of Co-Sale.  

		    (a)                     To
the extent the Company and the Investors do not exercise their respective
          rights of refusal as to all of the Offered Shares pursuant to Section 3.1, then
          each Investor (a “Selling Investor” for purposes
          of this Section 3.2) which notifies the Common Holder in writing within thirty
          (30) days after receipt of the Transfer Notice referred to in Section 3.1(a),
          shall have the right to participate in such sale of Offered Shares on the same
          terms and conditions as specified in the Transfer Notice. Such Selling
          Investor’s notice to the Common Holder shall indicate the number of shares
          of Equity Securities the Selling Investor wishes to sell under his, her or its
          right to participate. To the extent one or more of the Investors exercise such
          right of participation in accordance with the terms and conditions set forth
          below, the number of shares of Equity Securities that the Common Holder may
sell           in the Transfer shall be correspondingly reduced.  

		    (b)                     Each
Selling Investor may sell all or any part of that number of shares of           Equity
Securities equal to the product obtained by multiplying (i) the aggregate
          number of shares of Equity Securities covered by the Transfer Notice by (ii) a
          fraction, the numerator of which is the number of Equity Securities owned by
the           Selling Investor on the date of the Transfer Notice and the denominator of
which           is the total number of Equity Securities owned by the Common Holder and
all of           the Selling Investors on the date of the Transfer Notice.  

5 

		    (c)                     Each
Selling Investor shall effect its participation in the sale by promptly
          delivering to the Common Holder for transfer to the prospective purchaser one
or           more certificates, properly endorsed for transfer, which represent:  

		    (1)                     the
type and number of Equity Securities which such Selling Investor elects to
          sell; or  

		    (2)                     that
number of Equity Securities which are at such time convertible into the           number
of shares of Common Stock which such Selling Investor elects to sell;           provided,
however, that if the prospective third-party purchaser objects to the           delivery
of Equity Securities in lieu of Common Stock, such Selling Investor           shall
convert such Equity Securities into Common Stock and deliver Common Stock           as
provided in this Section 3.2. The Company agrees to make any such conversion
          concurrent with the actual transfer of such shares to the purchaser and
          contingent on such transfer.  

		    (d)                     The
stock certificate or certificates that the Selling Investor delivers to the
          Common Holder pursuant to Section 3.2(c) shall be transferred to the
prospective           purchaser in consummation of the sale of the Equity Securities
pursuant to the           terms and conditions specified in the Transfer Notice, and the
Common Holder           shall concurrently therewith remit to such Selling Investor that
portion of the           sale proceeds to which such Selling Investor is entitled by
reason of its           participation in such sale. To the extent that any prospective
purchaser or           purchasers prohibits such assignment or otherwise refuses to
purchase shares or           other securities from a Selling Investor exercising its
rights of co-sale           hereunder, the Common Holder shall not sell to such
prospective purchaser or           purchasers any Equity Securities unless and until,
simultaneously with such           sale, the Common Holder shall purchase such shares or
other securities from such           Selling Investor for the same consideration and on
the same terms and conditions           as the proposed transfer described in the
Transfer Notice.  

		    3.3.           Non-Exercise
of Rights. To the extent that the Company and the Investors           have not
exercised their rights to purchase the Offered Shares or the Remaining           Shares
within the time periods specified in Section 3.1 and the Investors have           not
exercised their rights to participate in the sale of the Offered Shares or           the
Remaining Shares within the time periods specified in Section 3.2, the           Common
Holder shall have a period of thirty (30) days from the expiration of           such
rights in which to sell the Offered Shares or the Remaining Shares, as the           case
may be, upon terms and conditions (including the purchase price) no more
          favorable than those specified in the Transfer Notice to the third-party
          transferee(s) identified in the Transfer Notice. The third-party transferee(s)
          shall acquire the Remaining Shares free and clear of subsequent rights of first
          refusal and co-sale rights under this Agreement. In the event the Common Holder
          does not consummate the sale or disposition of the Remaining Shares within the
          thirty (30) day period from the expiration of these rights, the Company’s
          first refusal rights and the Investors’ first refusal rights and co-sale
          rights shall continue to be applicable to any subsequent disposition of the
          Offered Shares or the Remaining Shares by the Common Holder until such right
          lapses in accordance with the terms of this Agreement.  

		    3.4.           Limitations
to Rights of Refusal and Co-Sale. Notwithstanding the           provisions of Section
3.1 and 3.2 of this Agreement, any Common Holder may, with           the written consent
of a majority in interest of the Investors (which consent           shall not be
unreasonably withheld), sell, transfer or otherwise assign, with or           without
consideration, Equity Securities to any spouse or member of such Common           Holder’s
immediate family, or to a custodian, trustee (including a trustee           of a voting
trust), executor, or other fiduciary for the account of the Common           Holder’s
spouse or members of the Common Holder’s immediate family, or           to a trust
for the Common Holder’s own self, or a charitable remainder           trust.  

6 

		    3.5.           Prohibited
Transfers. 

		    (a)                     In
the event a Common Holder should sell any Equity Securities in contravention           of
the co-sale rights under Section 3.2 (a “Prohibited           Transfer”),
the Investors, in addition to such other           remedies as may be available at law,
in equity or hereunder, shall have the put           option provided below, and the
Common Holder shall be bound by the applicable           provisions of such option.  

		    (b)                     In
the event of a Prohibited Transfer, each Investor shall have the right to           sell
to the Common Holder the type and number of shares of Equity Securities           equal
to the number of shares each Investor would have been entitled to transfer           to
the third-party transferee(s) under Section 3.2 hereof had the Prohibited
          Transfer been effected pursuant to and in compliance with the terms hereof.
Such           sale shall be made on the following terms and conditions:  

		    (1)                     The
price per share at which the shares are to be sold to the Common Holder           shall
be equal to the price per share paid by the third-party transferee(s) to           the
Common Holder in the Prohibited Transfer. The Common Holder shall also
          reimburse each Investor for any and all fees and expenses, including legal fees
          and expenses, incurred pursuant to the exercise or the attempted exercise of
the           Investor’s rights under Section 3.2.  

		    (2)                     Within
ninety (90) days after the later of the dates on which the Investor (A)
          received notice of the Prohibited Transfer or (B) otherwise became aware of the
          Prohibited Transfer, each Investor shall, if exercising the option created
          hereby, deliver to the Holder the certificate or certificates representing
          shares to be sold, each certificate to be properly endorsed for transfer.  

		    (3)                     The
Common Holder shall, upon receipt of the certificate or certificates for the
          shares to be sold by a Investor, pursuant to this Section 3.5, pay the
aggregate           purchase price therefor and the amount of reimbursable fees and
expenses, as           specified in subparagraph 3.5(b)(1), in cash or by other means
acceptable to the           Investor.  

		    4.           DRAG-ALONG
RIGHT. 

		    4.1.                     If
the holders of a majority of the Series A Stock (the “Triggering
          Investors”) shall approve in writing or by meeting, as
          evidenced by a writing reflecting such approval, a Sale, then the Company shall
          provide written notice of such approval (the “Sale           Notice”)
to the other Investors and the Common Holders           (collectively, the “Other
Holders”), which notice           shall include reasonable details of
the Sale, including the proposed time and           place of the closing and the
consideration to be received by the Triggering           Investors and the Other Holders.
Upon the expiration of a ten (10) day period           after the Other Holders receive
the Sale Notice, each of the Other Holders shall           be obligated to and shall: (a)
sell, transfer and deliver, or cause to be sold,           transferred and delivered, to
the proposed purchaser or transferee all of his,           her or its shares of capital
stock of the Company in the Sale at the closing           thereof on the same terms and
for the same consideration, according to the           different rights and preferences
of each class and series of capital stock of           the Company pursuant to the
Certificate, as that received by the Triggering           Investors (and deliver
certificates for such shares at the closing, free and           clear of all liens and
encumbrances); and (b) if stockholder approval of the           Sale is required, vote
all of his, her or its shares of capital stock of the           Company, or provide an
irrevocable proxy to vote his, her or its shares, in           favor thereof.
Notwithstanding the foregoing, no Triggering Investor or Other           Holder subject
to this Section 4 shall be required to make any representations           or warranties
or provide any indemnities in any agreement used to effect a Sale,           except
relating to ownership of capital stock of the Company by such Triggering
          Investor or Other Holder, their due execution of such agreement and the
          enforceability of such agreement as to such Triggering Investor or Other
Holder.  

7 

		    4.2.                     In
connection with a Sale, each of the Triggering Investors and Other Holders
          hereby expressly waives, to the extent permitted under applicable law, the
          applicability of the provisions for dissenters’ or appraisal rights set
          forth in Section 262 of the Delaware General Corporation Law, and expressly
          agrees that it shall not be entitled, under any circumstances in connection
with           such Sale, to exercise any such dissenters’ or appraisal rights.  

		    5.           PREEMPTIVE
RIGHT. 

		    5.1.           General.
Each Investor and any party to whom such           Investor’s rights under this
Section 5 have been duly assigned in           accordance with this Agreement has
the right of first refusal to purchase such           Investor’s Pro Rata Share (as
defined below), of all (or any part) of any           New Securities that the Company may
from time to time issue after the date of           this Agreement; provided that such
Investor (or permitted assignee) is an           “accredited investor” as such
term is defined in Regulation D under           the Securities Act. An Investor’s “Pro
Rata Share”          for purposes of this right of first refusal is the
ratio of (a) the number           of Equity Securities as to which such Investor is
the holder, to (b) the           number of issued and outstanding Equity Securities
of the Company.  

		    5.2.           Procedures.
In the event that the Company proposes to           undertake an issuance of New
Securities, it shall give to each Investor a           written notice of its intention to
issue New Securities (the “Notice”), describing the type of New
Securities and the           price and the general terms upon which the Company proposes
to issue such New           Securities, given in accordance with Section 8.2 hereof.
Each Investor           shall have twenty (20) days from the date such Notice is
effective, as           determined pursuant to Section 8.2 hereof based upon the
manner or method           of notice, to agree in writing to purchase such Investor’s
Pro Rata Share           of such New Securities for the price and upon the general terms
specified in the           Notice by giving written notice to the Company and stating
therein the quantity           of New Securities to be purchased (not to exceed such
Investor’s Pro Rata           Share). If any Investor fails to so agree in writing
within such twenty (20) day           period to purchase such Investor’s full Pro
Rata Share of an offering of           New Securities (a “Nonpurchasing
Investor”), then such           Nonpurchasing Investor shall forfeit the
right hereunder to purchase that part           of his Pro Rata Share of such New
Securities that he, she or it did not so agree           to purchase and the Company
shall promptly give each Investor who has timely           agreed to purchase his full
Pro Rata Share of such offering of New Securities (a “Purchasing Investor”)
written notice of the failure of           any Nonpurchasing Investor to purchase such
Nonpurchasing Investor’s full           Pro Rata Share of such offering of New
Securities (the “Overallotment           Notice”). Each
Purchasing Investor shall have a right of           overallotment such that such
Purchasing Investor may agree to purchase a portion           of the Nonpurchasing
Investors’ unpurchased Pro Rata Shares of such           offering on a pro rata
basis according to the relative Pro Rata Shares of the           Purchasing Investors, at
any time within five (5) days after receiving the           Overallotment Notice.  

8 

		    5.3.           Failure
to Exercise. In the event that the Investors fail           to exercise in
full the right of first refusal within such twenty (20) plus five           (5) day
period, then the Company shall have sixty (60) days thereafter to sell           the New
Securities with respect to which the Investors’ rights of first           refusal
hereunder were not exercised, at a price and upon general terms not           materially
more favorable to the purchasers thereof than specified in the           Company’s
Notice to the Investors. In the event that the Company has not           issued and sold
the New Securities within such sixty (60) day period, then the           Company shall
not thereafter issue or sell any New Securities without again           first offering
such New Securities to the Investors pursuant to this           Section 5.  

		    6.           BOARD
OF DIRECTORS. 

		    6.1.           Size
of Board of Directors. During the term of this Agreement,           each Investor
and each Common Holder, in his, her or its capacity as a holder of           the Company’s
Equity Securities, agrees to vote all Equity Securities now           or hereafter
directly or indirectly owned (of record or beneficially) by such           Investor or
Common Holder to maintain the authorized number of members of the           Board of
Directors of the Company at six (6) directors.  

		    6.2.           Election
of Board of Directors. 

		    (a)                     During
the term of this Agreement, each Investor and Common Holder agrees to           vote (in
accordance with the voting provisions of the Certificate) all Equity           Securities
now or hereafter directly or indirectly owned (of record or           beneficially) by
such Investor or Common Holder, in such manner as may be           necessary to elect
(and maintain in office):  

		    (1)                     One
(1) member of the Company’s Board of Directors designated by New           England
Partners Capital, L.P. (the “New England           Director”),
who shall initially be Ed Snape;  

		    (2)                     One
(1) member of the Company’s Board of Directors who shall be designated           by
Commonwealth Associates, L.P. (the “Commonwealth           Director”);  

		    (3)                     One
(1) member of the Company’s Board of Directors who shall be Albert           Henry
(the “CEO Director”);  

		    (4)                     One
(1) member of the Company’s Board of Directors who shall be Steven           Straus
(the “President Director”); and  

9 

		    (5)                     Two
(2) members of the Company’s Board of Directors who shall be designated           by
holders of a majority of the Series A Stock Holders (the “Series A
          Directors”), one of whom shall initially be Randolph C.
          Steer, M.D., Ph. D.  

		    (b)                     In
the event of the resignation, death, removal or disqualification of  

		    (1)                     the
New England Director, New England Partners Capital, L.P. shall promptly
          nominate a new director, and, after written notice of the nomination has been
          given to the other parties, each Investor and each Common Holder shall vote its
          Equity Securities to elect such nominee to the Board of Directors; or  

		    (2)                     the
Commonwealth Director, Commonwealth Associates, L.P. shall promptly nominate           a
new director, and, after written notice of the nomination has been given to           the
other relevant parties, each Investor and Common Holder shall vote their
          respective Equity Securities to elect such nominee to the Board of Directors;  

		    (3)                     the
CEO Director or the President Director, the remaining board members by
          unanimous written consent shall promptly nominate a new director who succeeds
to           the applicable management position, and, after written notice of the
nomination           has been given to the other relevant parties, each Investor and
Common Holder           shall vote their respective Equity Securities to elect such
nominee to the Board           of Directors; and  

		    (4)                     one
or more of the Series A Directors, the holders of the Series A Preferred           shall
promptly nominate a new director, and, after written notice of the           nomination
has been given to the other relevant parties, each Investor and           Common Holder
shall vote their respective Equity Securities to elect such           nominee to the
Board of Directors.  

		    6.3.           No
Liability for Election of Recommended Director. None of the           parties
hereto and no officer, director, stockholder, partner, employee or agent           of any
party makes any representation or warranty as to the fitness or           competence of
the nominee of any party hereunder to serve on the Board of           Directors by virtue
of such party’s execution of this Agreement or by the           act of such party in
voting for such nominee pursuant to this Agreement.  

		    7.           CERTAIN
COVENANTS 

		    7.1       Reverse
Merger. The           parties hereby acknowledge that the Company intends
to enter into a reverse           merger with and into a publicly traded entity whereby
the publicly traded entity           will be the surviving entity. The Company hereby
agrees that it will use its           best efforts to ensure the rights, preferences and
privileges of the Series A           Stock set forth in the Company’s Amended and
Restated Certificate of           Incorporation and the rights of the holders of such
Series A Stock set forth in           this Agreement the Amended and Restated
Registration Rights Agreement dated as           of even date herewith shall continue and
be adopted and agreed to by any such           surviving entity.  

10 

		    8.           REPRESENTATIONS
AND WARRANTIES 

		    8.1.                     Each
Common Holder represents and warrants to the Investors and the Company that           (a)
such Common Holder now owns the shares of Common Stock set forth next to           such
Common Holder’s name on Exhibit B, free and clear of liens or
          encumbrances, and has not, prior to or on the date of this Agreement, executed
          or delivered any proxy or entered into any other voting agreement or similar
          arrangement other than one which has expired or terminated prior to the date
          hereof, and (b) such Common Holder has full power and capacity to execute,
          deliver and perform this Agreement, which has been duly executed and delivered
          by, and evidences the valid and binding obligation of, such Common Holder
          enforceable in accordance with its terms.  

		    8.2.                     Each
Investor represents and warrants to the Investors and the Company that (a)           such
Investor now owns, or will own upon the Closing (as defined in the Series A
          Agreement), the number of shares of Series A Stock set forth next to such
          Investor’s name on Exhibit A, free and clear of any liens or
          encumbrances, and has not, prior to or on the date of this Agreement, executed
          or delivered any proxy or entered into any other voting agreement or similar
          arrangement other than one which has expired or terminated prior to the date
          hereof, and (b) such Investor has full power and capacity to execute, deliver
          and perform this Agreement, which ahs been duly executed and delivered by, and
          evidences the binding obligation of, such Investor in accordance with its
terms.  

		    9.           GENERAL
PROVISIONS. 

		    9.1.           Amendment
and Waiver of Rights. Any provision of this           Agreement may be
amended and the observance thereof may be waived (either           generally or in a
particular instance and either retroactively or           prospectively), only with the
written consent of (i) the Company, (ii) the           holders of a majority of the
Series A Stock (and/or any of their permitted           successors or assigns), and (iii)
a majority in interest of the Common Holders           (and/or any of their permitted
successors or assigns). Any amendment or waiver           effected in accordance with
this Section 9.1 shall be binding upon each           Investor, each Common Holder,
each permitted successor or assignee of such           Investor or Common Holder, and the
Company. Notwithstanding anything to the           contrary contained herein, if the
Company shall issue additional shares of its           Series A Stock, any purchaser
thereof shall become a party to this Agreement by           executing delivering an
additional counterpart signature page to this Agreement           and shall be deemed and
“Investor” and a party hereunder for all           purposes.  

		    9.2.           Notices.
Any and all notices required or permitted to be           given to a party pursuant to
the provisions of this Agreement will be in writing           and will be effective and
deemed to provide such party sufficient notice under           this Agreement on the
earliest of the following: (i) at the time of           personal delivery, if
delivery is in person; (ii) at the time of           transmission by facsimile,
addressed to the other party at its facsimile number           specified herein (or
hereafter modified by subsequent notice to the parties           hereto), with
confirmation of receipt made by both telephone and printed           confirmation sheet
verifying successful transmission of the facsimile;           (iii) one (1) business
day after deposit with an express overnight courier           for United States
deliveries, or two (2) business days after such deposit for           deliveries outside
of the United States, with proof of delivery from the courier           requested; or (iv) three
(3) business days after deposit in the United           States mail by certified mail
(return receipt requested) for United States           deliveries.  

11 

		    All notices
for delivery outside the United States will be sent by facsimile or by express courier.
Notices by facsimile shall be machine verified as received. All notices not delivered
personally or by facsimile will be sent with postage and/or other charges prepaid and
properly addressed to the party to be notified at the address or facsimile number as
follows, or at such other address or facsimile number as such other party may designate
by one of the indicated means of notice herein to the other parties hereto as follows: 

		    (a)        if
to an Investor, at such Investor’s respective address as set forth on Exhibit A hereto;  

		    (b)                     if
to the Company, marked “Attention: Chief Financial           Officer”,
at 2333 Waukegan Road, Suite 175, Bannockburn, IL 60015,           Facsimile: (847)
267-0518;  

		    (c)                     if
to a Common Holder, at such Common Holder’s respective address as set
          forth on Exhibit B hereto.  

		    9.3.           Assignment
of Rights. The rights of an Investor under this           Agreement may be
assigned only to: (i) any partner or retired partner of such           Investor which is
a partnership, (ii) any member or former member of such           Investor which is a
limited liability company, (iii) any family member or           trust for the
benefit of any individual Investor, (iv) any transferee who           acquires at least
one percent (1%) of the Company’s issued and outstanding           Equity
Securities, or (v) any affiliated venture capital fund of an Investor or           any
limited partner thereof, provided that the Company is, within a reasonable           time
after such transfer, furnished with written notice of the name and address           of
such transferee and the securities with respect to which such rights are           being
assigned, and such transferee or assignee shall be bound by and comply           with the
obligations of such Investor under this Agreement.  

		    9.4.           Additional
Equity Securities. In the event that subsequent to the           date of this
Agreement any Equity Securities are issued on, or in exchange for,           any of the
Common Stock and/or Series A Stock, as the case may be, held by the           Common
Holders and the Investors by reason of any stock dividend, stock split,
          combination of shares, reclassification or the like, such Equity Securities
          shall be deemed to be subject to the terms of this Agreement.  

		    9.5.           Legend. 

		    (a)                     Concurrently
with the execution of this Agreement, there shall be imprinted or           otherwise
placed, on certificates representing the Equity Securities held by the
          Investors and the Common Holders, the following restrictive legend           (“Legend”):  

	 	
“THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A
STOCKHOLDERS AGREEMENT WHICH PLACES CERTAIN RESTRICTIONS ON THE SHARES REPRESENTED
HEREBY. ANY PERSON ACCEPTING ANY INTEREST IN SUCH SHARES SHALL BE DEEMED TO AGREE TO AND
SHALL BECOME BOUND BY ALL THE PROVISIONS OF SUCH AGREEMENT. A COPY OF SUCH STOCKHOLDERS
AGREEMENT WILL BE FURNISHED TO THE RECORD HOLDER OF THIS CERTIFICATE WITHOUT CHARGE UPON
WRITTEN REQUEST TO THE COMPANY AT ITS PRINCIPAL PLACE OF BUSINESS.”

12 

		    (b)                     The
Company agrees that, during the term of this Agreement, it will not remove,           and
will not permit to be removed (upon registration of transfer, reissuance or
          otherwise), the Legend from any such certificate and will place or cause to be
          placed the Legend on any new certificate issued to represented the Equity
          Securities held by the Investors and the Common Holders theretofore represented
          by a certificate carrying the Legend.  

		    9.6.           Specific
Performance. The parties hereto hereby declare that it is           impossible to
measure in money the damages which will accrue to a party hereto           or to their
heirs, personal representatives, or assigns by reason of a failure           to perform
any of the obligations under this Agreement and agree that the terms           of this
Agreement shall be specifically enforceable. If any party hereto or his           heirs,
personal representatives, or assigns institutes any action or proceeding           to
specifically enforce the provisions hereof, any person against whom such           action
or proceeding is brought hereby waives the claim or defense herein that           such
party or such personal representative has an adequate remedy at law, and           such
person shall not offer in any such action or proceeding the claim or           defense
that such remedy at law exists.  

		    9.7.           Term.
This Agreement shall commence on the Effective Date and           shall terminate and
be of no further force or effect upon the first to occur of           (a) the date on
which a majority of the Series A Stock outstanding as of the           date hereof is no
longer outstanding whether by virtue of conversion, redemption           or repurchase,
or (b) a Sale.  

		    9.8.           Entire
Agreement. This Agreement and the documents referred           to herein,
together with all the Exhibits hereto and thereto, constitute the           entire
agreement and understanding of the parties with respect to the subject           matter
of this Agreement, and supersede any and all prior understandings and
          agreements, whether oral or written, between or among the parties hereto with
          respect to the specific subject matter hereof.  

		    9.9.           Governing
Law. This Agreement will be governed by and           construed in
accordance with the laws of the State of Delaware, without giving           effect to
that body of laws pertaining to conflict of laws.  

		    9.10.           Severability.
If any provision of this Agreement is           determined by any court or arbitrator of
competent jurisdiction to be invalid,           illegal or unenforceable in any respect,
such provision will be enforced to the           maximum extent possible given the intent
of the parties hereto. If such clause           or provision cannot be so enforced, such
provision shall be stricken from this           Agreement and the remainder of this
Agreement shall be enforced as if such           invalid, illegal or unenforceable clause
or provision had (to the extent not           enforceable) never been contained in this
Agreement. Notwithstanding the           foregoing, if the value of this Agreement based
upon the substantial benefit of           the bargain for any party is materially
impaired, which determination as made by           the presiding court or arbitrator of
competent jurisdiction shall be binding,           then both parties agree to substitute
such provision(s) through good faith           negotiations.  

13 

		    9.11.           Third
Parties. Nothing in this Agreement, express or           implied, is
intended to confer upon any person, other than the parties hereto           and their
successors and assigns, any rights or remedies under or by reason of           this
Agreement.  

		    9.12.           Successors
And Assigns. Subject to the provisions of           Section 9.3 of this
Agreement, the rights and obligations of the parties           hereunder will be binding
upon and inure to the benefit of their respective           successors, assigns, heirs,
executors, administrators and legal representatives.  

		    9.13.           Titles
and Headings. The titles, captions and headings of           this
Agreement are included for ease of reference only and will be disregarded           in
interpreting or construing this Agreement. Unless otherwise specifically
          stated, all references herein to “sections” and “exhibits” will
mean “sections”          and “exhibits” to
this Agreement.  

		    9.14.           Counterparts.
This Agreement may be executed in any number           of counterparts, each of which
when so executed and delivered will be deemed an           original, and all of which
together shall constitute one and the same agreement.  

		    9.15.           Costs
And Attorneys’ Fees. In the event that any           action, suit or
other proceeding is instituted concerning or arising out of this           Agreement or
any transaction contemplated hereunder, the prevailing party shall           recover all
of such party’s costs and attorneys’ fees incurred in each           such
action, suit or other proceeding, including any and all appeals or           petitions
therefrom.  

		    9.16.           Adjustments
for Stock Splits, Etc. Wherever in this           Agreement there is a
reference to a specific number of shares of Common Stock or           Preferred Stock of
the Company of any class or series, then, upon the occurrence           of any
subdivision, combination or stock dividend of such class or series of           stock,
the specific number of shares so referenced in this Agreement shall
          automatically be proportionally adjusted to reflect the affect on the
          outstanding shares of such class or series of stock by such subdivision,
          combination or stock dividend.  

		    9.17.           Aggregation
of Stock. All shares held or acquired by           affiliated entities or
persons shall be aggregated together for the purpose of           determining the
availability of any rights under this Agreement.  

		    9.18.           Further
Assurances. The parties agree to execute such           further documents
and instruments and to take such further actions as may be           reasonably necessary
to carry out the purposes and intent of this Agreement.  

		    9.19.           Facsimile
Signatures. This Agreement may be executed and           delivered by
facsimile and upon such delivery the facsimile signature will be           deemed to have
the same effect as if the original signature had been delivered           to the other
party.  

[Remainder of page
intentionally left blank] 

14 

        IN
WITNESS WHEREOF, the parties hereto have executed this Amended and Restated
Stockholders Agreement as of the date and year first written above. 

		
	"Company"	MSO Medical, Inc.
		 
		By:                                                                                                  
		      Albert Henry
		      Chairman and Chief Executive Officer

SIGNATURE PAGE TO
AMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

        IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Stockholders
Agreement as of the date first written above. 

		
	"Investor"	NAME OF INVESTING ENTITY
		                                                                                   
		 
		AUTHORIZED SIGNATORY
		 
		By:                                                                             
		Name:
		Title:
		 
		ADDRESS FOR NOTICE
		c/o:                                                                              
		Street:                                                                         
		City/State/Zip:                                                           
		Attention:                                                                   
		Tel:                                                                             
		Fax:                                                                             
		Email:                                                                          

SIGNATURE PAGE TO
AMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

        IN
WITNESS WHEREOF, the parties hereto have executed this Amended and Restated
Stockholders Agreement as of the date and year first written above. 

		
	"Common Holders"	Belusha, LLP
	 	 
		______________________________________________________________
By: Albert Henry, Its Partner
	 	 
		______________________________________________________________
James Sapala, M.D.
	 	 
		______________________________________________________________
Michael Wood, M.D.
	 	 
		______________________________________________________________
Michael Schuhkneckt, D.O.
	 	 
		______________________________________________________________
Larry Belenke

SIGNATURE PAGE TO
AMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

        IN
WITNESS WHEREOF, the parties hereto have executed this Amended and Restated
Stockholders Agreement as of the date and year first written above. 

		
	"Series A Preferred"	
		 
		______________________________________________________________
Richard Schoninger
		 
		______________________________________________________________
Bruce S. Schonbraun
		 
		______________________________________________________________
Richard Ullman
		 
		______________________________________________________________
Al Moschner
		 
		______________________________________________________________
Tim Ostrowski
		 
		______________________________________________________________
Mark Kubow
		 
		______________________________________________________________
John Lillard
		 
		American Constaine Insurance Company Limit
		 
		______________________________________________________________
Eric Rahn
		 
		______________________________________________________________
Ed Wehmer

SIGNATURE PAGE TO
AMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

        IN
WITNESS WHEREOF, the parties hereto have executed this Amended and Restated
Stockholders Agreement as of the date and year first written above. 

		
	"Series A Preferred"	
		______________________________________________________________
Frank Murnane, Jr.
		______________________________________________________________
Angelo Bufalino
		______________________________________________________________
Chris Perry
		______________________________________________________________
Patrick Salvi
		______________________________________________________________
Eric W. Rahn
		______________________________________________________________
Robin D. Rahn
		______________________________________________________________
Jamie R. Rahn
		______________________________________________________________
James D. Kensik
		______________________________________________________________
Steve Straus
		______________________________________________________________
Frank Bonvino

SIGNATURE PAGE TO
AMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

EXHIBIT A 

INVESTORS 

Harvard Development, Inc.

Ricky C. Sandler

Echo Capital Growth Corporation

Dr. Lloyd A. Moriber

CLK, Inc.

Terrence L. Mealy

Shea Ventures, LLC

New England Partners Capital, L.P.

Donald C. Carter

LBJ Holdings, LLC

RMC Capital, LLC

Morgan Investors X

Seneca Health Partners LP I

1991 Finlayson Family Trust

George K. Connor and Margaret A. Connor Family Trust

EXHIBIT B 

COMMON HOLDERS 

Belusha, LLP

James Sapala, M.D.

Michael Wood, M.D.

Michael Schuhnkneckt, D.O.

Larry Belenke

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]